OUR RESEARCH
MASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
OUR RESEARCH
MASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
News
2024
2023
2022
2021
2020
2019
Gannex Announces Poster Presentation Describing Positive Interim 12-Week Results from Ongoing 52-Week Phase II Clinical Trial of Once-Daily ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
11/06/2024
Gannex’s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
23/01/2024
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
02/01/2024
